Literature DB >> 29700002

Zika Virus Selectively Kills Aggressive Human Embryonal CNS Tumor Cells In Vitro and In Vivo.

Carolini Kaid1, Ernesto Goulart1, Luiz C Caires-Júnior1, Bruno H S Araujo2, Alessandra Soares-Schanoski3, Heloisa M S Bueno1, Kayque A Telles-Silva1, Renato M Astray3, Amanda F Assoni1, Antônio F R Júnior1, Daniella C Ventini3, Ana L P Puglia3, Roselane P Gomes3, Mayana Zatz4, Oswaldo K Okamoto4.   

Abstract

Zika virus (ZIKV) is largely known for causing brain abnormalities due to its ability to infect neural progenitor stem cells during early development. Here, we show that ZIKV is also capable of infecting and destroying stem-like cancer cells from aggressive human embryonal tumors of the central nervous system (CNS). When evaluating the oncolytic properties of Brazilian Zika virus strain (ZIKVBR) against human breast, prostate, colorectal, and embryonal CNS tumor cell lines, we verified a selective infection of CNS tumor cells followed by massive tumor cell death. ZIKVBR was more efficient in destroying embryonal CNS tumorspheres than normal stem cell neurospheres. A single intracerebroventricular injection of ZIKVBR in BALB/c nude mice bearing orthotopic human embryonal CNS tumor xenografts resulted in a significantly longer survival, decreased tumor burden, fewer metastasis, and complete remission in some animals. Tumor cells closely resembling neural stem cells at the molecular level with activated Wnt signaling were more susceptible to the oncolytic effects of ZIKVBR Furthermore, modulation of Wnt signaling pathway significantly affected ZIKVBR-induced tumor cell death and viral shedding. Altogether, these preclinical findings indicate that ZIKVBR could be an efficient agent to treat aggressive forms of embryonal CNS tumors and could provide mechanistic insights regarding its oncolytic effects.Significance: Brazilian Zika virus strain kills aggressive metastatic forms of human CNS tumors and could be a potential oncolytic agent for cancer therapy. Cancer Res; 78(12); 3363-74. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2018        PMID: 29700002     DOI: 10.1158/0008-5472.CAN-17-3201

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  IL-1 receptor antagonist therapy mitigates placental dysfunction and perinatal injury following Zika virus infection.

Authors:  Jun Lei; Meghan S Vermillion; Bei Jia; Han Xie; Li Xie; Michael W McLane; Jeanne S Sheffield; Andrew Pekosz; Amanda Brown; Sabra L Klein; Irina Burd
Journal:  JCI Insight       Date:  2019-02-28

Review 2.  Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.

Authors:  Jonathan G Pol; Sarah Lévesque; Samuel T Workenhe; Shashi Gujar; Fabrice Le Boeuf; Derek R Clements; Jean-Eudes Fahrner; Laetitia Fend; John C Bell; Karen L Mossman; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-08-27       Impact factor: 8.110

3.  miR-367 as a therapeutic target in stem-like cells from embryonal central nervous system tumors.

Authors:  Carolini Kaid; Dione Jordan; Heloisa Maria de Siqueira Bueno; Bruno Henrique Silva Araujo; Amanda Assoni; Oswaldo Keith Okamoto
Journal:  Mol Oncol       Date:  2019-08-22       Impact factor: 6.603

4.  Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade.

Authors:  Sharmila Nair; Luciano Mazzoccoli; Arijita Jash; Jennifer Govero; Sachendra S Bais; Tong Hu; Camila R Fontes-Garfias; Chao Shan; Hideho Okada; Sujan Shresta; Jeremy N Rich; Pei-Yong Shi; Michael S Diamond; Milan G Chheda
Journal:  JCI Insight       Date:  2021-01-11

Review 5.  Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas.

Authors:  Jiayi Zeng; Xiangxue Li; Max Sander; Haipeng Zhang; Guangmei Yan; Yuan Lin
Journal:  Front Immunol       Date:  2021-10-05       Impact factor: 7.561

Review 6.  Zika Virus: A New Therapeutic Candidate for Glioblastoma Treatment.

Authors:  Maria Giovanna Francipane; Bruno Douradinha; Cinzia Maria Chinnici; Giovanna Russelli; Pier Giulio Conaldi; Gioacchin Iannolo
Journal:  Int J Mol Sci       Date:  2021-10-12       Impact factor: 5.923

7.  Safety, Tumor Reduction, and Clinical Impact of Zika Virus Injection in Dogs with Advanced-Stage Brain Tumors.

Authors:  Carolini Kaid; Raquel Azevedo Dos Santos Madi; Renato Astray; Ernesto Goulart; Luiz Carlos Caires-Junior; Thiago Giove Mitsugi; Ana Carolina Ramos Moreno; Maria Fernanda Castro-Amarante; Lennon Ramos Pereira; Bruna Felício Milazzotto Maldonado Porchia; Thais Oliveira de Andrade; Vivian Landini; Daniel Soares Sanches; Carolina Gonçalves Pires; Rubens Koji Oliveira Tanioka; Marcia C L Pereira; Igor Neves Barbosa; Cristina O Massoco; Luís Carlos de Souza Ferreira; Oswaldo Keith Okamoto; Mayana Zatz
Journal:  Mol Ther       Date:  2020-03-10       Impact factor: 11.454

8.  Zika Virus with Increased CpG Dinucleotide Frequencies Shows Oncolytic Activity in Glioblastoma Stem Cells.

Authors:  Ivan Trus; Nathalie Berube; Peng Jiang; Janusz Rak; Volker Gerdts; Uladzimir Karniychuk
Journal:  Viruses       Date:  2020-05-25       Impact factor: 5.048

Review 9.  Oncolytic Viruses as a Platform for the Treatment of Malignant Brain Tumors.

Authors:  Jana de Sostoa; Valérie Dutoit; Denis Migliorini
Journal:  Int J Mol Sci       Date:  2020-10-09       Impact factor: 5.923

10.  Effect of Serial Systemic and Intratumoral Injections of Oncolytic ZIKVBR in Mice Bearing Embryonal CNS Tumors.

Authors:  Raiane Oliveira Ferreira; Isabela Granha; Rodolfo Sanches Ferreira; Heloisa de Siqueira Bueno; Oswaldo Keith Okamoto; Carolini Kaid; Mayana Zatz
Journal:  Viruses       Date:  2021-10-19       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.